Q4 2025 Cumberland Pharmaceuticals Inc Earnings Call Transcript

Mar 3, 2026 / 09:30 PM GMT

Release Date Price: $4.58 (-5.37%)

Transcript 10-K8-K

Key Points

Positve

Cumberland Pharmaceuticals Inc (CPIX) achieved a 31% increase in fourth-quarter revenues, totaling $13.7 million, and an 18% increase in full-year revenues, reaching $44.5 million.
The company strengthened its financial position by increasing shareholder equity and reducing its line of credit balance by over $10 million.
CPIX expanded its global presence with regulatory approvals in China and Mexico, and successful product launches in Saudi Arabia.
The company added Telicia, an FDA-approved treatment for Helicobacter pylori infections, to its portfolio, enhancing its presence in gastrointestinal care.
CPIX's clinical pipeline showed significant progress, with breakthrough results from the F DMD clinical study and FDA fast track designation for its DMD program.

Negative

CPIX faced increased operating expenses, rising from $12 million to $15 million in the fourth quarter, due to higher royalties and cost of goods.
The company reported a net loss of $1.4 million for the fourth quarter and $2.9 million for the full year, despite improvements over the previous year.
Crystallose faced increased substitution by pharmacies in favor of generic alternatives, impacting its sales.
The company has ongoing financial commitments, including milestone payments and royalties tied to product sales, which could impact future cash flow.
CPIX's total liabilities stood at $52.3 million, including $5.2 million on its credit facility, which could pose financial risks if not managed effectively.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CPIX.OQ - Cumberland Pharmaceuticals Inc
Q4 2025 Cumberland Pharmaceuticals Inc Earnings Call
Mar 03, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Cumberland Pharmaceutical 2025 financial report and company update. This call is being recorded at the company's request and will be archived on its website for one year from today's date.

And I turn it over to Emily Kent from Dalton Agency who handles Cumberland's communications. Emily, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its annual and 4th quarter financial results.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.